Novartis/QLT Visudyne Medicare Coverage Expansion Awaits More Data

The Centers for Medicare & Medicaid Services will ask for unpublished information from a peer-reviewed study of Novartis/QLT's Visudyne (verteporfin) for age-related macular degeneration before it expands coverage to off-label indications